US hematology specialist Disc Medicine (Nasdaq: IRON) today announced the appointment of Pamela Stephenson as the company’s chief commercial officer.
Ms Stephenson is an experienced biotech executive with more than 25 years of significant expertise in commercial and strategic leadership, particularly in therapies for rare diseases, and will be responsible for all aspects of Disc’s global commercialization strategy and execution.
Most recently, she served as the chief commercial officer of Albireo, which was acquired by French pharma firm Ipsen (Euronext: IPN) last year, spearheading the successful launch of Bylvay (odevixibat) for a rare cholestatic liver disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze